Literature DB >> 14557968

Danish bacille Calmette-Guérin vaccine-induced disease in human immunodeficiency virus-infected children.

A C Hesseling1, H S Schaaf, W A Hanekom, N Beyers, M F Cotton, R P Gie, B J Marais, P van Helden, R M Warren.   

Abstract

An analysis of isolates of Mycobacterium tuberculosis complex was performed to determine the prevalence of bacille Calmette-Guérin (BCG) disease among human immunodeficiency virus (HIV)-infected children. Speciation was done with polymerase chain reaction; 183 isolates from mycobacterial cultures for 49 HIV-infected patients were analyzed. The Danish Mycobacterium bovis BCG strain was isolated from 5 patients. No cases of Tokyo M. bovis BCG strain disease were detected. All patients were asymptomatic at birth, <12 months of age, and severely immunodeficient at presentation. Four patients had regional axillary adenitis ipsilateral to the vaccination site, and 2 had pulmonary BCG disease. Two patients with regional BCG disease had simultaneous pulmonary M. tuberculosis infection. Although chest radiographic features were similar to those seen in patients with tuberculosis, BCG disease should be considered in HIV-infected infants with right axillary adenitis ipsilateral to the vaccination site. Young, symptomatic, HIV-infected infants are at risk for BCG-related complications. Controlled, population-based studies are needed to assess the risk of BCG in HIV-infected children.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14557968     DOI: 10.1086/378298

Source DB:  PubMed          Journal:  Clin Infect Dis        ISSN: 1058-4838            Impact factor:   9.079


  29 in total

1.  Partial reconstitution of the CD4+-T-cell compartment in CD4 gene knockout mice restores responses to tuberculosis DNA vaccines.

Authors:  Sushila D'Souza; Marta Romano; Johanna Korf; Xiao-Ming Wang; Pierre-Yves Adnet; Kris Huygen
Journal:  Infect Immun       Date:  2006-05       Impact factor: 3.441

2.  Long-term protection against tuberculosis following vaccination with a severely attenuated double lysine and pantothenate auxotroph of Mycobacterium tuberculosis.

Authors:  Vasan K Sambandamurthy; Steven C Derrick; Kripa V Jalapathy; Bing Chen; Robert G Russell; Sheldon L Morris; William R Jacobs
Journal:  Infect Immun       Date:  2005-02       Impact factor: 3.441

Review 3.  BCG immunotherapy for bladder cancer--the effects of substrain differences.

Authors:  Christine Gan; Hugh Mostafid; Muhammad Shamim Khan; David J M Lewis
Journal:  Nat Rev Urol       Date:  2013-09-17       Impact factor: 14.432

4.  Evaluation of tuberculosis diagnostics in children: 2. Methodological issues for conducting and reporting research evaluations of tuberculosis diagnostics for intrathoracic tuberculosis in children. Consensus from an expert panel.

Authors:  Luis E Cuevas; Renee Browning; Patrick Bossuyt; Martina Casenghi; Mark F Cotton; Andrea T Cruz; Lori E Dodd; Francis Drobniewski; Marianne Gale; Stephen M Graham; Malgosia Grzemska; Norbert Heinrich; Anneke C Hesseling; Robin Huebner; Patrick Jean-Philippe; Sushil Kumar Kabra; Beate Kampmann; Deborah Lewinsohn; Meijuan Li; Christian Lienhardt; Anna M Mandalakas; Ben J Marais; Heather J Menzies; Grace Montepiedra; Charles Mwansambo; Richard Oberhelman; Paul Palumbo; Estelle Russek-Cohen; David E Shapiro; Betsy Smith; Giselle Soto-Castellares; Jeffrey R Starke; Soumya Swaminathan; Claire Wingfield; Carol Worrell
Journal:  J Infect Dis       Date:  2012-04-03       Impact factor: 5.226

5.  Mycobacterial codon optimization enhances antigen expression and virus-specific immune responses in recombinant Mycobacterium bovis bacille Calmette-Guérin expressing human immunodeficiency virus type 1 Gag.

Authors:  Masaru Kanekiyo; Kazuhiro Matsuo; Makiko Hamatake; Takaichi Hamano; Takeaki Ohsu; Sohkichi Matsumoto; Takeshi Yamada; Shudo Yamazaki; Atsuhiko Hasegawa; Naoki Yamamoto; Mitsuo Honda
Journal:  J Virol       Date:  2005-07       Impact factor: 5.103

6.  Priming-boosting vaccination with recombinant Mycobacterium bovis bacillus Calmette-Guérin and a nonreplicating vaccinia virus recombinant leads to long-lasting and effective immunity.

Authors:  Yasushi Ami; Yasuyuki Izumi; Kazuhiro Matsuo; Kenji Someya; Masaru Kanekiyo; Shigeo Horibata; Naoto Yoshino; Koji Sakai; Katsuaki Shinohara; Sohkichi Matsumoto; Takeshi Yamada; Shudo Yamazaki; Naoki Yamamoto; Mitsuo Honda
Journal:  J Virol       Date:  2005-10       Impact factor: 5.103

7.  Mycobacterium tuberculosis Rv0679c protein sequences involved in host-cell infection: potential TB vaccine candidate antigen.

Authors:  Diana P Cifuentes; Marisol Ocampo; Hernando Curtidor; Magnolia Vanegas; Martha Forero; Manuel E Patarroyo; Manuel A Patarroyo
Journal:  BMC Microbiol       Date:  2010-04-13       Impact factor: 3.605

8.  Lysine auxotrophy combined with deletion of the SecA2 gene results in a safe and highly immunogenic candidate live attenuated vaccine for tuberculosis.

Authors:  Joseph Hinchey; Bo Y Jeon; Holly Alley; Bing Chen; Michael Goldberg; Steven Derrick; Sheldon Morris; William R Jacobs; Steven A Porcelli; Sunhee Lee
Journal:  PLoS One       Date:  2011-01-10       Impact factor: 3.240

9.  Robust immunity to an auxotrophic Mycobacterium bovis BCG-VLP prime-boost HIV vaccine candidate in a nonhuman primate model.

Authors:  Gerald K Chege; Wendy A Burgers; Helen Stutz; Ann E Meyers; Rosamund Chapman; Agano Kiravu; Rubina Bunjun; Enid G Shephard; William R Jacobs; Edward P Rybicki; Anna-Lise Williamson
Journal:  J Virol       Date:  2013-02-28       Impact factor: 5.103

10.  Reduced rate of adverse reactions to the BCG vaccine in children exposed to the vertical transmission of HIV infection and in HIV-infected children from an endemic setting in Brazil.

Authors:  Regina Célia de Souza Campos Fernandes; Luciana Cordeiro de Araújo; Enrique Medina-Acosta
Journal:  Eur J Pediatr       Date:  2008-09-03       Impact factor: 3.183

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.